Ameritas Advisory Services’s ADMA Biologics ADMA Stock Holding History

Ameritas Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$9	–	1945
2026 Q1	$9	Buy	+1	New	+$16	﹤0.01%	1074
2025 Q4	–	Sell	-2,500	Closed	-$36.6K	–	938
2025 Q3	$36.6K	Hold	2,500	–	–	﹤0.01%	1204
2025 Q2	$45.5K	Buy	+2,500	New	+$51K	﹤0.01%	1354

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameritas Advisory Services's ADMA Position: Q2 2026 in Review

Ameritas Advisory Services sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 1 share — an estimated $9 sold.

Ameritas Advisory Services first reported a position in ADMA in Q2 2025 and held it in 3 quarters. The position peaked at $45.5K in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Ameritas Advisory Services reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Ameritas Advisory Services sold 1 ADMA Biologics share in Q2 2026, an estimated $9.
Ameritas Advisory Services first reported a position in ADMA Biologics in Q2 2025 and held it in 3 quarters.
Ameritas Advisory Services's ADMA Biologics position peaked at $45.5K in Q2 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.